Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Scientists Discover New Biological Marker for Parkinson's Disease

Published: Friday, September 20, 2013
Last Updated: Friday, September 20, 2013
Bookmark and Share
Researchers discover new biological indicator to track Parkinson’s disease using powerful MRI scanners.

Researchers in Nottingham have discovered a new biological indicator which could potentially help to track the progress of Parkinson’s disease using powerful MRI scanners.

Using highly sensitive new brain imaging techniques, scientists from The University of Nottingham and clinicians at Nottingham University Hospitals NHS Trust have discovered a measurable trait on the human brain which could be used not only to diagnose the condition but potentially also to track progression of the disease.

Parkinson’s develops when dopamine producing nerve cells in the brain die. Current diagnostic imaging tests using nuclear medical techniques are costly and cannot be used to monitor disease progression.

There has been a need for such imaging tracking in Parkinson’s disease to allow for the development of neuroprotective drugs through clinical trials.

In a paper published in the journal Neurology, the Nottingham researchers led by Penny, Gowland, Professor of Physics, reveal that this new discovery could potentially lead to a new diagnostic test for the disease.

Professor Gowland, who is based at the University’s Sir Peter Mansfield Magnetic Resonance Centre, said: “When conducting a different study of patients with Parkinson’s, by using a 7T MRI scanner (which is an extremely powerful MRI scanner), we discovered a mark which looked like a ‘tear drop’ on the brains of healthy subjects, and this was not visible in the brains of patients. In subsequent post mortem scans, we actually discovered that this was something called nigrosome 1. It was known from previous post mortem work that nigrosome 1 could not be found in brains of Parkinson’s disease patients.

‘So this was a breakthrough discovery in that we now know that using this particularly sensitive MRI scanner, we can see that patients living with Parkinson’s disease don’t have this particular feature in their brain.”

Now, researchers will take their findings and look into how this discovery can be translated into standard MRI scans used in most hospitals.

Professor Gowland added: “We are now conducting a study of patients with Parkinson’s to ascertain when this mark actually disappears, which could potentially have huge implications for early diagnosis of the illness, and subsequently how it is treated.”

Dr Nin Bajaj, Associate Honorary Clinical Professor in Neurology at Nottingham University Hospitals NHS Trust, said: “By using highly accurate and sensitive brain imaging techniques for Parkinson’s we are able to get an insight into the mechanism that causes the disease for the first time.

“We have been trying to find a biological marker for Parkinson’s for many years and the reason is that we need a tool to measure change in the disease in clinical trials in a very sensitive way. This discovery is a step change in Parkinson’s disease, it’s a game changer as they say and the implications are potentially huge.”

A full copy of the research paper can be viewed on the Neurology website. The research involved academics at The University of Nottingham’s Sir Peter Mansfield Magnetic Resonance Centre, Division of Radiological and Imaging Sciences and School of Psychology in collaboration with the Divisions of Pathology and Neurology at Nottingham University Hospitals NHS Trust.

The work was funded by the Medical Research Council and the Engineering and Physical Sciences Research Council (EPSRC).

The Sir Peter Mansfield Magnetic Resonance Centre is named after The University of Nottingham professor who played a central role in the development of MRI technology which revolutionized diagnostic medicine in hospitals around the world.

His contribution to the discovery earned him the Nobel Prize for Medicine in 2003.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Study Questions Presence in Blood of Heart-Healthy Molecules from Fish Oil Supplements
A new study from the Perelman School of Medicine at the University of Pennsylvania questions the relevance of fish oil-derived SPMs and their purported anti-inflammatory effects in humans.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Key Player in Diabetic Kidney Disease Revealed
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!